Publications by authors named "Mitali Alone"
Background: Neoadjuvant chemotherapy (NACT) with TPF (docetaxel, cisplatin, and 5FU) is one of the treatment options in very locally advanced oral cancer with a survival advantage over PF (cisplatin and 5FU). TP (docetaxel and cisplatin) has shown promising results with a lower rate of adverse events but has never been compared to TPF.
Methods: In this phase 3 randomized superiority study, adult patients with borderline resectable locally advanced oral cancers were randomized in a 1:1 fashion to either TP or TPF.
Purpose: There is a lack of published literature on systemic therapeutic options in cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) undergoing chemoradiation. Docetaxel was assessed as a radiosensitizer in this situation.
Methods: This was a randomized phase II/III study.
Article Synopsis
- - The study explored the effectiveness of adding low-dose nivolumab to a triple metronomic chemotherapy (TMC) regimen for patients with advanced head and neck squamous cell carcinoma, aiming to improve overall survival (OS) among those unable to afford conventional treatments.
- - Results showed that adding low-dose nivolumab significantly increased the one-year OS rate from 16.3% to 43.4% and improved the median OS from 6.7 months to 10.1 months when compared to TMC alone.
- - This research is notable as it is the first randomized trial demonstrating that low-dose nivolumab combined with metronomic chemotherapy can serve as a viable alternative for patients lacking access to conventional therapies
Salvage (Re)radiation in Oligometastatic and Oligorecurrent Cervical Cancer.
Int J Radiat Oncol Biol Phys
November 2022
Purpose: In patients with recurrent or metastatic cervical cancer, the median survival time is 13 to 24 months based on the choice of palliative systemic chemotherapy. Evolving evidence suggests that the addition of radiation may lead to improved survival.
Methods And Materials: Consecutive patients treated with radiation with or without systemic chemotherapy for oligometastatic or oligorecurrent disease within the period from 2017 to 2020 were included.
Purpose: Postoperative Adjuvant Radiation in Cervical Cancer (PARCER), a phase III randomized trial, compared late toxicity after image-guided intensity-modulated radiotherapy (IG-IMRT) with three-dimensional conformal radiation therapy (3D-CRT) in women with cervical cancer undergoing postoperative radiation.
Methods: Patients were randomly assigned to receive either IG-IMRT or 3D-CRT after stratification for the type of hysterectomy and use of concurrent chemotherapy. The primary end point was 3-year grade ≥ 2 late GI toxicity assessed using Common Toxicity Criteria for Adverse Events v 3.